EUVIMEDEUVIMED entdecken
Crossref

Systematic Identification and Recognition Analysis of Beta1‐Adrenergic Receptor Targeting Material Basis in Tibetan Medicine Formula Bawei Chenxiang Powder

Lixiang Chen, Yunzhi He, Junni Fan, Liangxi Li, Shasha Zhang, Mengze Wu, Yuxin Xie, Xinyi Yuan, Qian Li, Xu Ji iD

Journal of Molecular Recognition · 2026-01 · 39 (1)

DOI: 10.1002/jmr.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Recognition, online erschienen am 22.01.2026. Verfasst von Lixiang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Tibetan Medicine Detection Technology, Ministry of Education, Xizang Minzu University, Xianyang, Shaanxi, China. Hauptthemen laut MEDLINE: Receptors, Adrenergic, beta-1, Drugs, Chinese Herbal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tibet Autonomous Region, Engineering Research Center of the Ministry of Education of Tibetan Medicine Testing Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bawei Chenxiang Powder (BWCP) is a Tibetan medicine formulation used to treat cardiovascular diseases, has demonstrated clinical efficacy though its material basis remains unclear. In clinical trial, β 1 ‐adrenergic receptor (β 1 ‐AR) has been recognized as a key therapeutic target in cardiovascular disease treatment. So, in this work, we engineered a fusion protein by linking the kinase domain of epidermal growth factor receptor (EGFR) to the C‐terminus of β 1 ‐AR, which was subsequently immobilized onto the ibrutinib‐modified silica gels. Following column preparation by packing the β 1 ‐AR immobilized silica into a stainless‐steel column, the specificity and stability of β 1 ‐AR column were evaluated through the retention behavior analysis of atenolol, esmolol, and metoprolol for characterization. Then, using the β 1 ‐AR column combined with MS/MS, eight BWCP constituents targeting β 1 ‐AR were screened and identified: 6‐hydroxy‐2‐(2‐phenylethyl) chromone, taxifolin, myristicin, costunolide, dehydrocostus lactone, gallic acid, 3,4‐dihydroxybenzoic acid (DHBA), and catechin. The association constants of above screened compounds with immobilized β 1 ‐AR were (6.75 ± 0.05) × 10 4 , (13.2 ± 0.60) × 10 4 , (3.82 ± 0.18) × 10 4 , (145.13 ± 1.50) × 10 4 , (199.77 ± 0.30) × 10 4 , (13.8 ± 0.04) × 10 4 , (9.30 ± 0.14) × 10 4 , (31.4 ± 0.76) × 10 4 M −1 , respectively. Molecular docking results indicated that the compound‐β 1 ‐AR complexes stabilization primarily involves hydrogen bonding, van der Waals interactions, Pi‐alkyl, and Pi‐Pi stacking. A survey of DrugBank showed that catechin have well defined effects against cardiovascular diseases. DHBA and taxifolin are potential drug leads under experimental. These confirmed the reliability of the screened compounds by the immobilized β 1 ‐AR. To our knowledge, this work establishes the first systematic identification of BWCP's bioactive components targeting β 1 ‐AR, providing a pharmacological foundation for developing novel cardiovascular therapeutics derived from this traditional formulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Adrenergic, beta-1Drugs, Chinese HerbalMolecular Docking SimulationPowdersHumansTandem Mass Spectrometry

Stichwörter der Autor:innen

BaWei Chenxiang powderTibetan medicineimmobilized beta1‐adrenoceptormaterial basisreceptor chromatography

Substanzen

Receptors, Adrenergic, beta-1Drugs, Chinese HerbalPowders

Autor:innen und Institutionen

  • Engineering Research Center of Tibetan Medicine Detection Technology, Ministry of Education, Xizang Minzu University, Xianyang, Shaanxi, China.
  • Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Shaanxi, China.

ORCID-Profile: Xu Ji

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Tibet Autonomous Region
  • Engineering Research Center of the Ministry of Education of Tibetan Medicine Testing Technology

Zitieren

APA

Chen, L., He, Y., Fan, J., Li, L., Zhang, S., Wu, M., Xie, Y., Yuan, X., Li, Q., & Ji, X. (2026). Systematic Identification and Recognition Analysis of Beta1‐Adrenergic Receptor Targeting Material Basis in Tibetan Medicine Formula Bawei Chenxiang Powder. Journal of Molecular Recognition, 39(1). https://doi.org/10.1002/jmr.70022

Vancouver

Chen L, He Y, Fan J, Li L, Zhang S, Wu M, et al. Systematic Identification and Recognition Analysis of Beta1‐Adrenergic Receptor Targeting Material Basis in Tibetan Medicine Formula Bawei Chenxiang Powder. Journal of Molecular Recognition. 2026;39(1). doi:10.1002/jmr.70022

BibTeX
@article{Chen2026,
  author = {Chen, Lixiang and He, Yunzhi and Fan, Junni and Li, Liangxi and Zhang, Shasha and Wu, Mengze and Xie, Yuxin and Yuan, Xinyi and Li, Qian and Ji, Xu},
  title = {Systematic Identification and Recognition Analysis of Beta1‐Adrenergic Receptor Targeting Material Basis in Tibetan Medicine Formula Bawei Chenxiang Powder},
  journal = {Journal of Molecular Recognition},
  year = {2026},
  volume = {39},
  number = {1},
  doi = {10.1002/jmr.70022}
}
Kostenlos starten →